TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is:
- A multicenter, prospective, randomized, phase 3 trial.
- To prove non-inferiority of Taxotere/Cisplatin compared to Pemetrexed/Cisplatin as a
front line treatment of patients with non-squamous cell lung cancer.
- 276 patients will be recruited.